Day: May 20, 2024

Presentations highlight new VCIEL scale to measure small intestinal mucosal health and research from rich database of latiglutenase Phase 2 clinical trials BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) — Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, yesterday presented two posters on celiac disease research at the 2024 Digestive Disease Week (DDW 2024) Conference in Washington, D.C. The presentations draw upon research from the robust clinical program investigating latiglutenase, an oral biotherapeutic being developed as a potentially first-in-class, targeted, oral biotherapeutic for celiac disease (CeD). The results from these presentations demonstrate...

Arecor Therapeutics plc(“Arecor” or “the Company”) AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETESAT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI Confirms previous trial results in people with Type 1 diabetes, demonstrating AT278 can maintain fast and superior onset of action and glucose lowering profile irrespective of diabetes type and BMI Enables delivery of a highly concentrated, low volume injection, offering more effective mealtime glucose control to meet growing unmet need in patients requiring high daily doses of insulin Creates potential to be the first, and only, ultra-concentrated (500 U/mL) ultra-rapid insulin product...

Ageas and Taiping deepen cooperation in pension solutions Ageas announces today that following confirmation of its participation in the capital increase tender in November 2023, an agreement has been concluded with China Taiping Insurance Holdings (CTIH) to subscribe to the capital increase of its wholly controlled subsidiary Taiping Pension Co., Ltd (“TPP”) for a total consideration of RMB 1,075 million (around EUR 137 million)*. After closing of the transaction Ageas will hold 10% of the enlarged share capital of TPP. The investment in TPP will allow Ageas to tap into the significant growth potential of the Chinese pension market, capitalising on the increasing demand for personal pension products in China. It also helps Ageas to strengthen its presence in the largest growth market in Asia, diversify its business offerings, and consolidate...

SHENZHEN, China, May 20, 2024 (GLOBE NEWSWIRE) — Aesthetic Medical International Holdings Group Limited (Nasdaq: AIH) (the “Company” or “AIH”), a leading provider of aesthetic medical services in China, today announced that it has received a determination letter of the Hearings Panel (the “Panel”) of The Nasdaq Capital Market (“Nasdaq”) dated May 17, 2024, notifying the Company that the Panel determined to delist the Company’s securities from Nasdaq, due to the failure to satisfy the continued listing conditions as previously disclosed. As a result, the Company expects that its securities will be suspended from trading at the open of business on May 21, 2024 and delisted from Nasdaq after the completion of Nasdaq’s filing of a Form 25 Notification of Delisting with the Securities and Exchange Commission after all appeal periods...

BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use. Kionex® Suspension is the only commercially available therapeutically equivalent to the reference listed drug (RLD) SPS® Suspension for Oral or Rectal use. “The launch of Kionex® Suspension for Oral or Rectal use exemplifies our capability to bring complex generics with limited market competition to our customers and patients in need. This launch is especially meaningful given the complexity of the development and is a testament to the tireless efforts of our strong R&D team to meet the updated guidance from the U.S. Food and Drug Administration,” stated Nikhil Lalwani, President and Chief Executive Officer...

Bayport Management Ltd announces standstill agreement and is in constructove negotiations with creditiors to address its capital structure, cash interest obligations and debt maturitiesAttachmentsBayport Management Limited – Market Announcement – 20 May 2024Bayport Management Limited – Market Announcement – 20 May 2024

DAYTONA BEACH, Fla., May 20, 2024 (GLOBE NEWSWIRE) — Bridge Specialty Group, LLC (“Bridge Specialty”) is very pleased to welcome Public Entities of America, LLC (“PEA”) to its team of niche-focused, wholesale entities. PEA is a leading brokerage agency working exclusively in the public sector and risk management marketplace. PEA teammates will join the team at Apex Insurance Agency, LLC (“Apex”) and work alongside leaders Michelle Hill, Apex vice president, and Karl Snearer, Apex president and regional leader for Bridge Specialty. Snearer commented, “We are very excited to welcome the PEA team to Apex and Bridge Specialty. Their team has established itself as an industry leader providing innovative risk solutions for the public sector across the United States and bring additional public entity capabilities and talented insurance...

ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Spyridon “Spyros” Papapetropoulos, M.D., PhD, President and Chief Executive Officer of Bionomics will be giving an oral presentation and presenting two posters about BNC210 as a potential treatment for social anxiety disorder and post-traumatic stress disorder (PTSD) at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place May 28 – 31 in Miami Beach, Florida. Details of the presentations are as follows: Presentation title: Positive...